Eli Lilly (LLY) Cash & Equivalents (2009 - 2026)

Eli Lilly (LLY) has reported Cash & Equivalents for 18 consecutive years, with $5.3 billion the latest figure, recorded in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $5.3 billion, up 70.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 billion (up 70.76% YoY), and the FY2025 annual result was $7.3 billion, up 122.4% from the prior year.
• Cash & Equivalents was $5.3 billion for Q1 2026 at Eli Lilly, down from $7.3 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $9.8 billion in Q3 2025 and troughed at $2.1 billion in Q4 2022.
• Average Cash & Equivalents over 5 years is $3.7 billion, with a median of $3.1 billion recorded in 2025.
• Year-over-year, Cash & Equivalents plunged 45.87% in 2022 and soared 190.65% in 2025.
• Over 5 years, Cash & Equivalents stood at $2.1 billion in 2022, then surged by 36.36% to $2.8 billion in 2023, then advanced by 15.94% to $3.3 billion in 2024, then soared by 122.4% to $7.3 billion in 2025, then dropped by 27.33% to $5.3 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $5.3 billion in Q1 2026, $7.3 billion in Q4 2025, and $9.8 billion in Q3 2025.